治疗后游离PSA比值能否预测复发性前列腺癌的不良结局?
单中心回顾性队列研究(NCT03927287)纳入822例局限性前列腺癌治疗后生化复发患者,评估治疗后游离PSA比值(FPSAR)对转移、去势抵抗性前列腺癌(CRPC)和癌症特异性生存(CSS)的预测价值。FPSAR切点定为0.10,<0.10者中位无转移生存和CRPC无进展生存更长,≥0.10与转移和CRPC风险增加相关,并在Biobank队列中验证。
要点
- 治疗后FPSAR≥0.10与更侵袭性疾病相关。
- FPSAR<0.10者中位无转移生存和CRPC无进展生存更长。
- FPSAR≥0.10与RP和RT队列转移风险增加独立相关。
核心结论
- 治疗后FPSAR≥0.10与更具侵袭性的疾病相关,提示该生物标志物可能具有新用途。
研究设计与样本
- 单中心回顾性队列研究(NCT03927287),发现队列纳入2000至2017年根治性前列腺切除(RP)或放疗(RT)后行FPSAR检测的患者。
- 验证队列为独立的Biobank RP后生化复发患者队列。
- 共分析822例患者(305例RP、363例RT和154例Biobank患者)。
主要发现
- RP队列中FPSAR<0.10者中位无转移生存为14.8年,≥0.10者为9.3年;RT队列分别为14.8年和13年。
- RP队列中FPSAR<0.10者中位CRPC无进展生存未达到,≥0.10者为9.9年;RT队列分别为20.7年和13.8年。
- 多变量分析显示FPSAR≥0.10与RP队列转移风险增加相关(HR 1.915,95%CI 1.241-2.955),与RT队列转移风险增加相关(HR 1.754,95%CI 1.112-2.769)。
- FPSAR≥0.10与RP队列CRPC风险增加相关(HR 2.470,95%CI 1.493-4.088)。
- 上述发现在Biobank队列中得到验证。
关键数值与推荐
- 通过受试者工作特征分析在RP和RT队列中确定FPSAR切点为0.10。
临床怎么用
- 治疗后生化复发时可考虑检测FPSAR,FPSAR≥0.10提示需更密切监测和积极干预。
局限性
- 研究为单中心回顾性设计,部分FPSAR检测为偶然或反射性进行,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether free PSA ratio (FPSAR) at biochemical recurrence (BCR) can predict metastasis, castrate-resistant prostate cancer (CRPC), and cancer-specific survival (CSS), following therapy for localised disease. PATIENTS AND METHODS: A single-centre retrospective cohort study (NCT03927287) including a discovery cohort composed of patients with an FPSAR after radical prostatectomy (RP) or radiotherapy (RT) between 2000 and 2017. For validation, an independent Biobank cohort of patients with BCR after RP was tested. Using a defined FPSAR cut-off, the metastasis-free-survival (MFS), CRPC-free survival, and CSS were compared. Multivariable Cox models determined the association between post-treatment FPSAR, metastases, and CRPC. RESULTS: Overall, 822 patients (305 RP- and 363 RT-treated patients and 154 Biobank patients) were analysed. In the RP cohort, a total of 272/305 (89.1%) and 33/305 (10.9%) had a FPSAR test incidentally and reflexively, respectively. In the RT cohort, 155/363 (42.7%) and 208/263 (57.3%) had a FPSAR test incidentally and reflexively, respectively. However, in the prospective Biobank RP cohort, FPSAR testing was done on all samples of patients diagnosed with BCR. A FPSAR cut-off of 0.10 was determined using receiver operating characteristic analyses in both the RP and RT cohorts. A FPSAR of <0.10 resulted in longer median MFS (14.8 vs 9.3 years and 14.8 vs 13 years, respectively), and longer median CRPC-free survival (median not reached vs 9.9 years and 20.7 vs 13.8 years, respectively). Multivariable analyses showed that a FPSAR of ≥0.10 was associated with increased metastasis in the RP cohort (hazard ratio [HR] 1.915, 95% confidence interval [CI] 1.241-2.955) and RT cohort (HR 1.754, 95% CI 1.112-2.769), and increased CRPC in the RP cohort (HR 2.470, 95% CI 1.493-4.088). Findings were validated in the Biobank cohort. CONCLUSIONS: A post-treatment FPSAR of ≥0.10 is associated with more aggressive disease, suggesting a potentially novel role for this biomarker.
引用
- Goldberg H, Glicksman R, Woon D, et al. Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer? BJU Int. 2020. PMID: 32926761. doi:10.1111/bju.15236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。